Finance

Lists
ZTS:NYSE
Zoetis Inc
USD 79,72
+1,85%
(+1,45) 1D
USD 79,00
-0,90% (-0,72)
After hours
Closed: 30 Okt., 16:00:08 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZTS...
Open
USD 79,84
High
USD 80,60
Low
USD 79,22
Mkt. cap
32,94 mjd
Avg. vol.
4,09 m
Volume
4,12 m
Dividend
2,66%
Quarterly dividend
USD 0,53
Ex-dividend date
30 Okt. 2026
P/E ratio
13,11
52-wk high
USD 144,83
52-wk low
USD 68,77
EPS
USD 6,08
Beta
0,74
Shares outstanding
413,22 m
No. of employees
14 k
Open
USD 79,84
High
USD 80,60
Low
USD 79,22
Mkt. cap
32,94 mjd
Avg. vol.
4,09 m
Volume
4,12 m
Dividend
2,66%
Quarterly dividend
USD 0,53
Ex-dividend date
30 Okt. 2026
P/E ratio
13,11
52-wk high
USD 144,83
52-wk low
USD 68,77
EPS
USD 6,08
Beta
0,74
Shares outstanding
413,22 m
No. of employees
14 k
News stories
From web sources and news partners
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14,5 k
Founded1952
HeadquartersParsippany-Troy Hills, New Jersey, Verenigde State van Amerika
SectorPharmaceutical industry
Websitezoetis.com
Analyst ratings
Based on 12 analysts giving stock ratings to ZTS in the past 3 months
Buy
Buy
4
Hold
8
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ZTS in the last 3 months.
Highest
Current USD 79,72
USD 115,00 (+44,25%)
Average
USD 88,22 (+10,66%)
Lowest
USD 74,00 (-7,18%)
Analyst
Recommendation
Action
Price target
Projected
Date
Erin Wright
Morgan Stanley
Buy
Reiterated
USD 82,00
+2,9%
10/30/2026
Andrea Alfonso
UBS
Hold
Reiterated
USD 85,00
+6,6%
10/27/2026
Keith Devas
Jefferies
Hold
Downgraded
USD 83,00
+4,1%
10/20/2026
Chris Schott
J.P. Morgan
Buy
Maintained
USD 115,00
+44,3%
10/16/2026
Matthew Dellatorre
Goldman Sachs
Hold
Initiated
USD 74,00
-7,2%
10/16/2026
Daniel Clark
Leerink Partners
Hold
Reiterated
-
-
10/01/2026
Jonathan Block
Stifel Nicolaus
Hold
Reiterated
-
-
09/18/2026
Steve Scala
TD Cowen
Buy
Reiterated
USD 94,00
+17,9%
08/25/2026
Glen Santangelo
Barclays
Hold
Reiterated
USD 85,00
+6,6%
08/17/2026
Daniel Grosslight
Citi
Buy
Maintained
USD 96,00
+20,4%
08/11/2026
David Westenberg
Piper Sandler
Hold
Maintained
USD 80,00
+0,4%
08/10/2026
Ryan Daniels
William Blair
Hold
Downgraded
-
-
08/06/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
07/28/2026
Sidharth Sahoo
HSBC
Buy
Maintained
USD 95,00
+19,2%
07/06/2026
Jasper Hellweg
Argus Research
Hold
Downgraded
-
-
05/26/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
05/08/2026
Thomas DeBourcy
Nephron
Hold
Downgraded
USD 131,00
+64,3%
03/05/2026
Mark Massaro
BTIG
Buy
Reiterated
USD 160,00
+100,7%
02/26/2026
Next call oor 6 dae
Do. 5 Nov., 15:30
Fiscal period
Q3 2026
- / USD 1,51
Revenue / Est. (USD)
- / 2,30 mjd
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,40 mjd
2,39 mjd
2,26 mjd
2,47 mjd
Cost of goods sold
682,00 m
711,00 m
640,00 m
670,00 m
Cost of revenue
682,00 m
711,00 m
640,00 m
670,00 m
Research and development expenses
170,00 m
199,00 m
180,00 m
173,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
572,00 m
618,00 m
584,00 m
589,00 m
Operating expense
774,00 m
848,00 m
795,00 m
793,00 m
Total operating expenses
1,46 mjd
1,56 mjd
1,44 mjd
1,46 mjd
Operating income
944,00 m
828,00 m
827,00 m
1,00 mjd
Other non operating income
-
-6,00 m
-1,00 m
-2,00 m
EBT including unusual items
887,00 m
761,00 m
758,00 m
866,00 m
EBT excluding unusual items
899,00 m
780,00 m
779,00 m
948,00 m
Income tax expense
166,00 m
158,00 m
157,00 m
175,00 m
Effective tax rate
18,71%
20,76%
20,71%
20,21%
Other operating expenses
-
-
-
-
Net income
721,00 m
603,00 m
601,00 m
691,00 m
Net profit margin
30,04%
25,26%
26,57%
28,00%
Earnings per share
1,70
1,48
1,53
1,87
Interest and investment income
26,00 m
25,00 m
21,00 m
16,00 m
Interest expense
-58,00 m
-57,00 m
-62,00 m
-61,00 m
Net interest expenses
-32,00 m
-32,00 m
-41,00 m
-45,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,07 mjd
903,00 m
946,00 m
1,12 mjd
Gain or loss from assets sale
-
-
-6,00 m
-1,00 m
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google-programme